Terumo Interventional Systems’ Runthrough NS Hypercoat is a complex lesion wire specifically for tortuous, distal lesions and tight stenotic lesions. It features an enhanced hydrophilic coating on the distal tip (25 cm), providing superior* trackability to reach the distal regions of tortuous anatomy.1,2

The nitinol core-to-tip design enables reuse in multiple lesions within complex percutaneous coronary intervention (PCI), and may reduce wire use per case and cost to the facility. Additionally, the thermal memory of nitinol provides superior* tip durability in complex PCI.2 The low tip weight and high tip flexibility is designed to enable the wire to easily and safely knuckle while traversing into distal vessels, as well as allow for easy prolapse (and may contribute to safety as it relates to distal perforations). Its 14-mm-long shapeable segment enables custom shaping of the guidewire tip, with superior tip shape retention.2 This facilitates navigation through tortuous anatomy and offers flexibility to address a wider range of clinical scenarios.

1. Lewis S. Value of the Terumo RUNTHROUGH® NS Coronary Guidewire. Diagnostic & Invasive Cardiology. http://www.dicardiology.com/content/value-terumo-runthrough-ns-coronary-guidewire. March/April 2008. Accessed September 1, 2015.

2. Runthrough NS Hypercoat Bench Testing. Test Report. March 20, 2015 (data on file).

*Compared to workhorse wire category of guidewires.

Boston Scientific Corporation has announced US Food and Drug Administration approval and the United States launch of the Innova Vascular self-expanding stent system. The Innova Stent is approved for use in the superficial femoral artery (SFA) and/or proximal popliteal arteries.

“The SFA and proximal popliteal arteries present a challenging environment for stents. The flexibility, radial strength, and fracture resistance of the Innova stent are designed specifically for this anatomy,” said Richard Powell, MD, Section Chief, Department of Vascular Surgery, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire; Professor of Surgery and Radiology at Geisel School of Medicine; and global Principal Investigator of the SuperNOVA trial.

The Innova stent system consists of a nitinol self-expanding stent with an advanced delivery system and is available in diameters from 5 to 8 mm and lengths of 20 to 200 mm. It features hybrid cell architecture with open cells for flexibility and closed cells for uniform and accurate deployment. The intuitive triaxial delivery system provides precise, predictable stent placement and uniform deployment. This stent platform serves as the foundation for the company’s new Eluvia drug-eluting vascular stent,* designed specifically for the SFA.

*Eluvia is not available for sale in the United States.